Is the price fair?
What PVLA's price assumes
Palvella Therapeutics, Inc. did not earn a profit over the last twelve months, so it has no trailing P/E and the price is read against sales instead: 560× revenue.
560
Price / sales · no P/E: the last twelve months did not end in a profit
- Price / book
- 7.02
Price / book · as of 2026-Q1
Details›
- Price / book2026-Q1
- 7.02
- Market capitalisation
- $1.62B
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.